C4 Therapeutics Files 8-K on Corporate Governance
Ticker: CCCC · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
C4 Therapeutics filed an 8-K on June 18, 2025, detailing corporate governance and financial statement updates.
AI Summary
On June 18, 2025, C4 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. No specific financial figures or significant corporate actions were detailed in the provided excerpt.
Why It Matters
This filing indicates updates to C4 Therapeutics' corporate structure and governance, which are important for investors to understand the company's operational framework and compliance.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new material financial information or significant business changes that would immediately impact risk.
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Registrant
- June 18, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-39567 (identifier) — Commission File Number
- 47-5617627 (identifier) — IRS Employer Identification No.
- 490 Arsenal Way, Suite 120 Watertown, MA 02472 (address) — Business Address
FAQ
What specific amendments were made to C4 Therapeutics' articles of incorporation or bylaws?
The provided excerpt of the 8-K filing does not detail the specific amendments made to the articles of incorporation or bylaws.
What matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not included in the provided text.
Are there any new financial statements included with this filing?
Yes, the filing indicates that financial statements and exhibits are included, but the content of these statements is not detailed in the excerpt.
What is the primary purpose of this 8-K filing for C4 Therapeutics?
The primary purpose of this 8-K filing is to report on amendments to articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits.
When was C4 Therapeutics incorporated?
C4 Therapeutics, Inc. was incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding C4 Therapeutics, Inc. (CCCC).